ArticleMolecular psychiatry2026
A nuclei-specific fronto-amygdala pathway and its neurotransmitter receptor distribution: Implications for Antidepressant Selection.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The amygdala and its cortical connections play an important role in antidepressant treatment of major depressive disorder (MDD). While it can be subdivided according to its cortical connections, the anatomical and molecular heterogeneity across these subdivisions in MDD patients responding to different antidepressants remain unclear. Therefore, we aimed to investigate whether nuclei-level cortico-amygdala white matter (WM) connectivity differentiates responses to two first-line treatments - selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI); and to clarify the molecular underpinnings of such difference. From diffusion tensor imaging data in a discovery cohort of 106 MDD patients who response to SSRI (SSRI-Improvers) or SNRI (SNRI-Improvers), cortico-amygdala WM connectivity was estimated via probabilistic tractography. K-modes clustering was applied to cluster the amygdala into subdivisions by cortical projections. Fractional anisotropy (FA) values of each cortico-subdivision WM connection were then compared between SSRI-Improvers and SNRI-Improvers. Finally, the discriminative WM connection was decoded using microscale transcriptomic and chemo-architecture analysis, and its relevance was validated in an independent replication cohort of 66 MDD patients through targeted single-nucleotide polymorphisms (SNP) genotyping. A key difference in WM connection between frontal lobe and medial amygdala nucleus (medialAMY) was identified, which refers to a pharmacological propensity pattern. Such pattern was aligned with the serotonin and noradrenaline neurotransmitter system in a group-specific manner, and mediated the effects of genetic risks of SLC6A4 on treatment inclination. The convergence of macroscale pharmacological propensity connectome, microscale molecular architecture, and genetic variation provides new testable evidence to inform decision-making in antidepressant treatment of MDD.
Indexed as
Identifiers
41748920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.